Greenwich LifeSciences (NASDAQ:GLSI – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.06, FiscalAI reports.
Greenwich LifeSciences Price Performance
Greenwich LifeSciences stock traded up $0.05 during trading hours on Tuesday, reaching $15.55. The company had a trading volume of 107,206 shares, compared to its average volume of 237,813. The company has a 50-day moving average price of $19.16 and a 200 day moving average price of $23.53. The firm has a market cap of $228.27 million, a price-to-earnings ratio of -9.90 and a beta of 1.46. Greenwich LifeSciences has a 12-month low of $7.78 and a 12-month high of $34.10.
Insiders Place Their Bets
In related news, CEO Snehal Patel acquired 2,500 shares of the company’s stock in a transaction dated Thursday, July 23rd. The stock was purchased at an average price of $13.14 per share, with a total value of $32,850.00. Following the completion of the purchase, the chief executive officer owned 5,606,602 shares in the company, valued at $73,670,750.28. This trade represents a 0.04% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders purchased a total of 5,800 shares of company stock valued at $76,618 in the last ninety days. Insiders own 51.47% of the company’s stock.
Institutional Inflows and Outflows
Analyst Ratings Changes
Several equities analysts recently commented on the stock. HC Wainwright increased their target price on shares of Greenwich LifeSciences from $50.00 to $69.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Wall Street Zen downgraded shares of Greenwich LifeSciences from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Greenwich LifeSciences in a research report on Friday, May 15th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $57.00.
Check Out Our Latest Report on Greenwich LifeSciences
Greenwich LifeSciences Company Profile
Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.
Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.
Featured Stories
- Five stocks we like better than Greenwich LifeSciences
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
